Miao Xue; Yanqin Wu; Wenzhe Fan; Jian Guo; Jialiang Wei; Hongyu Wang; Jizhou Tan; Yu Wang; Wang Yao; Yue Zhao; Jiaping Li

doi:10.4143/crt.2019.533

Articles

Page Path: HOME > Cancer Res Treat > Volume 52(3); 2020 > Article

Original Article Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma: Miao Xue, MD, Yanqin Wu, MD, PhD, Wenzhe Fan, MD, PhD, Jian Guo, MD, Jialiang Wei, MD, Hongyu Wang, MD, Jizhou Tan, MD, Yu Wang, MD, PhD, Wang Yao, MD, Yue Zhao, MD, PhD, Jiaping Li, MD, PhD; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2020;52(3):925-937.
DOI: https://doi.org/10.4143/crt.2019.533
Published online: March 30, 2020

Department of Interventional Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

Correspondence: Jiaping Li, MD, PhD Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan 2 Road, 510080, Guangzhou, China
Tel: 86-13352890908 Fax: 86-020-87755766 E-mail: lijiaping_2011@126.com

^*Miao Xue, Yanqin Wu, and Wenzhe Fan contributed equally to the study.

• Received: September 17, 2019 • Accepted: March 28, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

11,740 Views
154 Download
21 Web of Science
20 Crossref
20 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
This study aimed to investigate the clinicopathologic features and mutational landscape of patients with hepatitis B virus (HBV)–related advanced hepatocellular carcinomas (HCC) undergoing transcatheter arterial chemoembolization (TACE).
Materials and Methods
From January 2017 to December 2018, 38 patients newly diagnosed with HBV-related advanced HCC were enrolled in the final analysis. Their pathological tissues and corresponding blood samples before TACE treatment were collected for whole-exome sequencing. Response to TACE was evaluated at 1-3 months after two consecutive use of TACE. Predictive factors were analyzed by univariate and multivariate analyses in a bivariate Logistic regression model. Enrichment of related pathways of all driver genes were acquired using the gene set enrichment analysis (GSEA).
Results
Among 38 patients, 23 (60.5%) exhibited TACE failure/refractoriness. Patients with TACE failure/refractoriness showed higher frequency of TP53 mutation than their counterparts (p=0.020). Univariate and multivariate analyses showed that only vascular invasion and TP53 mutation were significantly correlated with TACE failure/refractoriness in HBV-related advanced HCC. Of the 16 patients without vascular invasion, eight (50.0%) had TP53 mutations, and TP53 mutation was associated with TACE failure/refractoriness (p=0.041). Moreover, GSEA showed that mitogen-activated protein kinase and apoptosis pathways induced by TP53 mutation were possibly associated with TACE failure/refractoriness.
Conclusion
Our study suggested that TP53 mutation was independently related with TACE efficacy, which may work via mitogen-activated protein kinase and apoptosis pathways. These findings may provide evidence to help distinguish patients who will particularly benefit from TACE from those who require more personalized therapeutic regimens and rigorous surveillance in HBV-related advanced HCC.
Key words: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Whole-exome sequencing, Treatment outcome, Tumor response, Tumor protein p53

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide and the third most common cause of cancer death, especially in Asia. Hepatitis B virus (HBV) was the most common cause of HCC [1]. Despite the surveillance programs to diagnose early liver tumors in cirrhotic patients, most HCCs are currently diagnosed at advanced stages. Based on Chinese specific national conditions and practical experience, the following HCC staging scheme is recommended, including stage Ia, Ib, IIa, IIb, IIIa, IIIb, and IV. Stage IIb is defined as tumor numbers ≥ 4 without extrahepatic metastasis or vascular invasion. Stage IIIa is defined as tumors with vascular invasion and without extrahepatic metastasis. All stage IIb or IIIa patients have Child-Pugh class A or B and performance status (PS) 0-2. In China, transcatheter arterial chemoembolization (TACE) is an approved first-line therapy for stage IIb or IIIa patients [2,3].

Response rates to TACE are heterogeneous. Age, liver function, α-fetoprotein, tumorlocation, tumor size, and tumor number are the reported risk factors for TACE therapy in patients with HCC [4,5]. According to JSH-LCSGJ Criteria 2014 Update, these patients who cannot benefit from ≥ 2 TACE therapy were considered as TACE failure/refractoriness. TACE failure/refractoriness is defined as insufficient response including intrahepatic lesion (viable lesion of > 50% or tumor number increases as compared to tumor number before the previous TACE procedure), continuous elevation of tumor markers, appearance of vascular invasion or extrahepatic spread after two or more consecutive use of superselective TACE [6]. However, survival may vary widely among patients with HCC with similar clinicopathologic features. Then, more accurate predictors should be identified to discriminate patients who will benefit from TACE therapy from those with TACE failure/refractoriness.

Genetic profiling, to date, has revealed broad diversity as regards recurrent genomic alterations in HCC. Moreover, a large number of samples have provided an accurate landscape of genetic alterations and biomarkers [7]. It was reported that TP53 and CTNNB1 can affect 25-30% of HCC. For example, mutated genes affect the cell cycle (TP53), WNT signaling (CTNNB1 and AXIN1) or chromatin remodeling (ARID1A and ARID2) [8]. Besides, mutated driver genes, for example, JAK1, MYC, NOTCH, BRCA, PTEN, SOX2, FGF3, and RB1, may be related with HCC prognosis. As most genomic studies had been conducted in early HCC and almost all samples were obtained through liver resection, only one study depicted the genetic determinants of HCCs from early stages to advanced stages [9]. However, how genes affected the tumor response of patients treated with TACE remains unknown.

Therefore, this study aimed to investigate and analyze the clinicopathologic features and mutational landscape of HBV-related advanced HCC undergoing TACE, which will help design more comprehensive biomarkers to guide clinical practice.

Materials and Methods

1. Patients and tumor samples

A total of 138 patients newly diagnosed with unresectable HCC admitted to The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, between January 2017 and December 2018 were recruited. HCC was diagnosed based on histological criteria according to the Chinese standard treatment for HCC in 2017 [3]. All patients were included in our study if they (1) underwent TACE as the first treatment, (2) were 18-75 years, (3) were classified as IIb or IIIa according to Chinese standard treatment for HCC in 2017 [3], (4) had Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1, (5) had Child-Pugh class A or B, and (6) had history of HBV infection. Patients were excluded if they (1) had serious medical comorbidities, such as hepatic encephalopathy, uncontrolled ascites, severe coagulation disorders, current infection and serious heart or kidney dysfunction (i.e., total bilirubin, > 100 μmol/L; prothrombin activity, < 40%; or platelet count, < 20×10⁹/L), (2) currently had other malignancies or history of other malignancies, (3) had undergone other treatments before (i.e., liver resection, liver transplantation, radiofrequency ablation, targeted drugs, or immune checkpoint inhibitors), (4) had major portal vein tumor thrombosis or extrahepatic metastasis, (5) had history of hepatitis C virus infection, alcoholism, or other etiologies. All samples were obtained by computed tomography (CT)–guided puncture biopsy and were immediately frozen in liquid nitrogen and stored at –80°C before the extraction. Then, their global gene expression pattern was analyzed using whole-exome sequencing (WES) from 38 HBV-related advanced patients.

2. WES analysis

In this study, total exosomes from 38 HBV-related advanced HCC tumor tissues were sequenced. SureSelect Human All Exome Kit V5 (Agilent Technologies, Santa Clara, CA) was used to fragment and hybridize DNA which contained 27,000 exon sequences. Exome shotgun libraries were sequenced on Illumina Xten platforms, generating 150 bp paired reads at each end. Imaging analysis and baseline calls were made using CAVSAVR (Illumina, San Diego, CA) with default parameters. Sequencing adapters and low quality reads were removed for high quality reads. The genes were compared with NCBI human reference genome hg19 using the Burrows Wheeler alignment algorithm.

3. TACE procedure

TACE procedures were performed by two of three experienced interventional radiologists (W.F., Y.W., and J.L.). Hepatic angiography was performed by placing a 5-F catheter (Terumo, Tokyo, Japan) or a 2.7-F microcatheter (Renegade Hi-Flo Straight, Boston Scientific, Natick, MA; Progreat, Terumo) as superselectively as possible into tumor-feeding arteries. An emulsion of 5-20 mL lipiodol (Lipiodol, Guerbet, Aulnay-Sous-Bois, France) or drug-loaded microspheres (DC-Bead [DCB], SciClone, Shanghai, China) and 20-80 mg of epirubicin (Pharmorubicin, Pfizer, New York, NY) were administered into feeder vessels. Then, 350-560-mm absorbable gelatin sponge particles (Gelfoam, Hangzhou Pharmaceutical, Hangzhou, China) were administered into tumor-feeding vessels. Particle size of DCB microspheres were selected according to angiogr-aphic blood flow velocity. After embolization, angiography of the feeding artery was performed to determine the extent of vascular occlusion. If reflux occurred, the use of lipiodol, DCB microspheres, or absorbable gelatin sponge particles will be discontinued.

4. Evaluation of TACE response

In our study, TACE failure/refractoriness is defined as insufficient response including intrahepatic lesion (viable lesion of > 50% or tumor number increases as compared to tumor number before the previous TACE procedure), continuous elevation of tumor markers, progression of vascular invasion, or appearance of extrahepatic spread after two consecutive use of superselective lipiodol or DCB TACE [9]. Tumor assessment was performed at 1-3 months using CT or magnetic resonance scan after two conecutive use of TACE. Group A patients were included when TACE failure/refractoriness occurred at 1-3 months. Other patients were automatically entered into group B and considered effectively treated with TACE therapy.

5. Statistical analyses

All statistical analyses were performed using SPSS software ver. 24.0 (IBM Corp., Armonk, NY) and Graphpad Prism 7 software (GraphPad Software Inc., San Diego, CA). Proportions were compared using the Fisher exact chi-square test (the total number of cases, < 40) or Pearson’s chi-squared test (total number of cases, ≥ 40). Univariate and multivariate analysis were performed using the bivariate Logistic regression model. All statistical tests were two-tailed, and p < 0.05 indicated a significant difference.

6. Ethical statement

All study protocols were conducted according to the ethical guidelines of the “World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects.” This study was approved by the Institutional Review Board of the Research Institute and Hospital National Cancer Center (IRB No. [2018] 43). This study was approved by the institutional review board of The First Affiliated Hospital, Sun Yat-sen University. All patients provided written informed consent.

Results

1. Study population and HCC characteristics at baseline

A total of 38 patients with HBV-related advanced HCC were enrolled and clearly diagnosed by pathological biopsy in this study (Fig. 1), with demographic, clinical, and tumor staging features depicted in Table 1. There was no difference of histologic criteria between China and the World Health Organization. Among them, 37 patients were men (97.4%); seven (38.9%) had Child-Pugh class B; more than half of patients had vascular invasion (57.9%) and two or more lesions (77.8%); and eight (44.4%) had a maximum tumor size of > 5 cm (Table 1, Fig. 1).

2. Overview of genetic alterations in 38 patients with HBV-related advanced HCC

Results of gene mutations were obtained from all 38 patients using the WES technique. A total of 186 potential driver genes were screened. The most significantly mutated genes are as follows: two genes that have been previously established to be mutated in HCC (TP53, CTNNB1) and four genes known to be frequently mutated in other cancer types (MYC, JAK1, FGF, and BRCA) (Table 2). Among them, TP53 had the highest prevalence of altering mutations identified in our study (22/38, 57.9%) (Fig. 2), which was consistent with that of previous studies.

3. Significant mutated genes and clinical features between different response groups

According to the criterion mentioned above, 23 patients were entered into group A and considered TACE failure/refractoriness, whereas other 15 patients belonged to group B and they could benefit from TACE therapy. Between the two groups, TP53 mutation was the only driver gene significantly different in our study (p=0.020) (Table 3, Fig. 2). In particular, mutation frequency of hotspot R249S was higher in group A than group B. But no significant difference was shown in hotpot mutations such as R249S (p=0.371), G59V E68*, R65*, W146*, V157F, E171*, E221 Rfs*25, C229Yfs*10, M246V (Fig. 3A and B). Moreover, increased gene expression in group A was observed for FLG (6/23 samples) as compared with group B. Meanwhile, increased gene expression in group B was observed for CSMD2 (4/15 samples), JARID2 (4/15), GBA2 (3/15), IGSF3 (3/15), IQCJ-SCHIP1 (3/15), KIAA1731 (3/15), LGI2 (3/15), OR10X1 (3/15), PRKRIR (3/15), RNF145 (3/15), and SH3BP4 (3/15) (Fig. 2). With regard to clinical characteristics, we found that vascular invasion, aspartate transaminase, Child-Pugh class, and ECOG PS were significantly higherin group A than that group B (Table 4).

4. TP53 mutation and vascular invasion as predictive factors for TACE failure/refractoriness

Univariate analysis showed that Child-Pugh class (odds ratio [OR], 15.273; 95% confidence interval [CI], 1.714 to 136.126; p=0.015), ECOG PS score (OR, 0.145; 95% CI, 0.031 to 0.677; p=0.014), vascular invasion (OR, 19.000; 95% CI, 3.604 to 100.154; p=0.001), TP53 mutation (OR, 5.667, 95% CI, 1.369 to 23.462; p=0.017) were significantly correlated with TACE failure/refractoriness. On multivariate analysis, vascular invasion (OR, 18.204, 95% CI, 1.392 to 238.090; p=0.027) and TP53 mutation (OR, 13.287, 95% CI, 1.114 to 158.451; p=0.041) were significantly correlated with TACE failure/refractoriness (Table 5, Fig. 4). Then, we did subgroup analysis depending on presence or absence of vascular invasion. Of the 16 patients without vascular invasion, eight (50.0%) had TP53 mutations, and TP53 mutation was associated with TACE failure/refractoriness (p=0.041). Of the 22 patients with vascular invasion, 14 (63.6%) had TP53 mutations, and there was no correlation between TP53 mutation and TACE failure/refractoriness (p=0.386) (Table 6).

5. Frequently altered cancer pathways related to TP53 mutation status

Then, pathway enrichment analyses of genes harboring somatic single nucleotide polymorphism or copy number variations were performed using the gene set enrichment analysis (GSEA) technique from MsigDB for TP53 mutation. Frequent alterations across multiple pathways, including Wnt, JAK/STAT, G1/S cell cycle, mitogen-activated protein kinase (MAPK), and apoptosis were identified. MAPK and apoptosis pathway were found to drive TACE failure/refractoriness. MAPK signaling pathway included TP53, FAS, NFATC4, HSPA1B, FLNA, and RASGRF2 mutation, whereas apoptosis signaling pathway included TP53, FAS, PIK3CA, and CSF-2RB mutation. Among them, PIK3CA and HSPA1B were detected in 17.39% of patients in group A and 0% in group B. They induced the activation of BAD by promoting apoptosis. DNA biosynthesis was observed in group A, with E2F4 mutated in 13.04% and E2F2 in 4.34% of patients (Fig. 5).

Discussion

To our knowledge, few data are available regarding the genetic mechanism of TACE failure/refractoriness for HBV-related advanced HCC. This study is the first report to describe the correlations between TACE failure/refractoriness and genetic alteration in HBV-related advanced HCC.

This study found that TP53 had the highest frequency (57.9%) of mutations in HBV-related advanced HCC. However, in COSMIC database, TP53 mutation accounted for approximately 27% of all samples with mutation. The frequency of TP53 mutation in our series which was higher than any previous reports could be explained by a difference of etiologies and tumor staging. Woo et al. [10] had demonstrated that TP53 mutation was associated with poor prognosis in Chinese patients with HCC with HBV infection. HBV infection affects the IncRNA expression, which can also affect p53 stability [11]. Nault et al. [9] also reported that advanced-stage HCC (Barcelona Clinic Liver Cancer [BCLC] B/C) showed higher frequencies of TP53 mutation. Then, to determine the possible genetic mechanism related to TACE efficacy, heatmap of significantly somatic genetic alterations was compared between TACE failure/refractoriness (group A) and TACE effective (group B) groups. Among all driver genes, only the frequency of TP53 mutation was found to be significantly higher in group A than that in group B. Among all hotpots in TP53 mutation, mutation frequency of hotspot R249S was higher in group A than that in group B, but no significant difference was shown in all hotpots, including R249S. Currently, the specific mechanism of TP53 mutation on TACE failure/refractoriness, especially hotspot such as R249S, is still unclear.

To further elaborate the relationship between TP53 mutation and TACE efficacy, the following univariate and multivariate analyses were performed. We found that only TP53 mutation and vascular invasion were possible predictive factors of TACE failure/refractoriness. Then, we did subgroup analysis depending on presence or absence of vascular invasion. We found that TP53 mutation was significantly correlated with TACE failure/refractoriness only when vascular invasion was absent. It meant for stage BCLC B patients, TP53 mutation was more likely to drive TACE failure/refractoriness.

Tumor hypoxia induced by TACE therapy is the possible mechanism of TACE failure/refractoriness. Kamat et al. [12] reported that with higher hypoxia inducible factor-1α levels in response to chronic hypoxia, p53-mutant (MUT) cells could favor cell survival and tumor progression. Tumor protein p53 plays a central role in cellular DNA damage responses. Recent studies have shown that accelerated cell proliferation, increased metastasis, and apoptosis resistance were found in the TP53-MUT group [13]. Speidel [14] reported that TP53 is upregulated and activated by genotoxic stress and promotes apoptosis, cell cycle arrest, senescence, and DNA repair. Therefore, compared with p53-wild-type (WT) cells, p53-MUT cells are more likely to induce TACE failure/refractoriness because of metastasis and apoptosis resistance of HCC cells. Furthermore, accumulating evidence showed that hotspot mutations of TP53 mutation such as R249S were strongly associated with poor prognosis [10]. R249S may be associated with hepatitis B virus X protein, which is expressed from hepatocyte-integrated HBV associated with HCC development [15,16]. Besides, vascular invasion was reported as the single impediment to long-term survival in patients with HBV-related HCC who underwent resection and/or ablation after TACE and increased the risk of TACE failure/refractoriness [17,18]. Oda et al. [19] found that in most multinodular HCCs, there are different TP53 mutation patterns in different nodules, indicating that heterogeneous cell clones could promote HCC cells proliferation, vascular invasion, and extrahepatic metastasis. Therefore, in HBV-related Stage BCLC B HCCs, comprehensive treatment is needed when TP53 mutation is present.

Subsequently, GSEA pathway enrichment analysis was performed to elaborate on the discrepancy of related pathways between groups A and B. Therefore, MAPK and apoptosis pathways were found to be related to TACE efficacy. As signaling pathways downstream from targets of TP53 mutation, MAPK and apoptosis pathways could abrogate the dependence of HCCs on TACE treatment and thus may mediate TACE failure/refractoriness. However, the specific mechanism remains to be identified. MAPK/ERK signaling pathways play central roles in cancer cell metabolic adaptation, which promotes liver cancer cell proliferation [20]. HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signaling pathway [21]. Apoptosis-related pathway induces the expression of apoptosis-related proteins in HCC cells and promotes vascular invasion and extrahepatic metastasis [22]. Thus, the activation of MAPK and apoptosisrelated pathways induced by TP53 mutation could drive TACE failure/refractoriness.

Our study was limited because of several points. First, it was conducted in a small cohort of patients, and all data were obtained from a single center. To address this limitation, more clinical and genomic data are expected to be collected with higher number of patients and research centers. Second, this was a retrospective (not prospective) study, which may reduce the reliability of data. This mostly led to a selection bias. Third, genetic factors were part of biological factors influencing TACE failure/refractoriness; therefore, more evaluating indicators and circulating cell-free DNA are encouraged.

In conclusion, vascular invasion and TP53 mutation were predictive factors of TACE failure/refractoriness in HBV-related advanced HCC. TP53 mutation was independently related with TACE efficacy, which may work via MAPK and apoptosis pathways. However, further studies regarding their specific mechanism remain to be conducted.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

The major scientific and technological project of Guangdong Province (No. 2017B030308006). The major program for tackling key problems of Guangzhou City, China (No. 201704020144) and National Natural Science Foundation of China (NSFC) (No. 81671797). We thank GenomiCare Biotechnology (Shanghai) Co., Ltd. for the sequencing services and technical support.

Fig. 1.

Flow chart of enrolled patients. HCC, hepatocellular carcinoma; WES, whole-exome sequencing; TACE, transcatheter arterial chemoembolization; CT, computed tomography; MRI, magnetic resonance imaging.

Fig. 2.

Heatmap of somatic genetic alterations in significant variation genes between groups A and B. Group A is defined as a group where transcatheter arterial chemoembolization (TACE) failure/refractoriness. And group B is defined as a group which can benefit from TACE therapy. Top and right panel shows the frequency of somatic mutation, middle panel shows patients ID, mutational spectra of single-nucleotide variants in different group, and types of mutation are indicated in the legend at the bottom (n=38). We found that the occurrence probability of TP53 and FLG mutations in the invalid group was significantly higher than that in group A. T>G mutation did not occur in group A during the transformation and alteration.

Fig. 3.

Distribution of somatic mutations in the TP53 gene. The structural domains of TP53 mutations were different between the two groups, and the occurrence probability of TP53 R249S mutation in group A was higher than that in group B. Alteration frequency was represented as a percentage of significant variation genes in two groups: the left box represents group A and the right represents group B. Alteration types and frequencies were represented by different colors and color gradients, respectively.

Fig. 4.

TP53 mutated and wild-type cases were compared before and after transcatheter arterial chemoembolization (TACE) by using computed tomography (CT) scan. For TP53 mutated case in A, plain sweep, augmentation, and portal phase were shown respectively in a, b, and c before TACE, while they were shown in d, e, and g after TACE. We found that TACE failure/refractoriness was assessed in the TP53 mutated case. Meanwhile, the TP53 wild-type case was shown in B and effective for TACE. The two cases were evaluated according to the criteria mentioned above.

Fig. 5.

Frequently altered cancer pathways for TP53 using gene set enrichment analysis pathway enrichment in hepatocellular carcinoma. Core pathway analysis identified frequent genomic alterations in multiple cancer pathways including mitogen-activated protein kinase and apoptosis. MAPK, mitogen-activated protein kinase.

Table 1.

Baseline characteristics of enrolled HCC patients

Characteristic	No. (%) (n=38)
Age, mean±SD (yr)	50±11.5
Sex (male/female)	37/1
Cirrhosis (present/absent)	33/5
Ascites (present)	12 (31.6)
Maximum tumor size (> 5 cm)	21 (55.3)
Tumor number (multifocal)	29 (76.3)
Vascular invasion	22 (57.9)
ALB (g/L)	37.4±16.6
TBIL (μmol/L)	16.3±20.8
PT (sec)	12.4±0.9
AFP (> 400 ng/mL)	21 (55.3)
ECOG PS (0/1)	19/19
Child-Pugh (A/B)	31/7
BCLC stage (B/C)	16/22

HCC, hepatocellular carcinomas; ALB, albumin; TBIL, total bilirubin; PT, prothrombin time; AFP, α-fetoprotein; ECOG, Eastern Cooperative Oncology Group; PS, performance status; BCLC, Barcelona Clinic Liver Cancer.

Table 2.

Significantly mutated genes in 38 HBV-related advanced HCC patients

Gene	Gene description	No. of patients	Sites
TP53	Tumor protein p53	22	21
MYC	Proto-oncogene, bHLH transcription factor	9	-
FGF	Fibroblast growth factor	9	-
BRCA	DNA repair associated	8	8
JAK1	Janus kinase 1	6	5
NOTCH	Neurogenic locus notch homolog	6	6
SOX2	SRY-box transcription factor 2	5	-
CTNNB1	Catenin beta 1	5	4
PTEN	Phosphatase and tensin homolog	4	3
RB1	RB transcriptional corepressor 1	4	4
TERT (exons)	Telomerase reverse transcriptase	3	3
RAS	Resistance to audiogenic seizures	3	-
ALK	Receptor tyrosine kinase	1	1

HBV, hepatitis B virus; HCC, hepatocellular carcinomas; -, none.

Table 3.

The association of driver genes mutation and TACE failure/refractoriness

	Group A (n=23)	Group B (n=15)	p-value
TP53
No mutation	6	10
Mutation (+)	17	5	0.020
MYC
No mutation	16	13
Mutation (+)	7	2	0.273
FGF
No mutation	16	13
Mutation (+)	7	2	0.273
BRCA
No mutation	18	12
Mutation (+)	5	3	0.371
JAK1
No mutation	15	12
Mutation (+)	3	3	0.663
NOTCH
No mutation	19	13
Mutation (+)	4	2	1.000
SOX2
No mutation	20	13
Mutation (+)	3	2	1.000
CTNNB1
No mutation	21	12
Mutation (+)	2	3	0.365
PTEN
No mutation	20	14
Mutation (+)	3	1	1.000
RB1
No mutation	19	15
Mutation (+)	4	0	0.138
TERT (exons)
No mutation	21	14
Mutation (+)	2	1	1.000
RAS
No mutation	23	12
Mutation (+)	0	3	0.054
ALK
No mutation	23	14
Mutation (+)	0	1	0.395

TACE, transcatheter arterial chemoembolization; TP53, tumor protein p53; MYC, proto-oncogene; FGF, fibroblast growth factor; JAK1, Janus kinase 1; NOTCH, neurogenic locus notch homolog; SOX2, SRY-box transcription factor 2; CTNNB1, catenin beta 1; PTEN, phosphatase and tensin homolog; RB1, RB transcriptional corepressor 1; TERT, telomerase reverse transcriptase; ALK, anaplastic lymphoma kinase; -, none.

Table 4.

Clinical characteristic in 38 HBV-related advanced HCC patients

Variable	Group A (n=23)	Group B (n=15)	p-value
Age (yr)
≤ 50	14	7	0.509
> 50	9	8
Cirrhosis
Absence	3	2	> 0.99
Presence	20	12
Ascites
Absence	17	13	0.440
Presence	6	2
Maximum tumor size (cm)
≤ 5	9	9	0.320
> 5	14	6
Tumor number
Simple	8	5	> 0.99
Multiple	15	10
Vascular invasion
Absence	4	12	< 0.001
Presence	19	3
WBC (×10⁹/L)
≤ 10	19	14	0.630
> 10	4	1
NEUT (×10⁹/L)
≤ 6.4	17	14	0.209
> 6.4	6	1
HB (g/L)
≤ 120	7	2	0.273
> 120	16	13
PLT (×10⁹)
≤ 100	4	2	> 0.99
> 100	19	13
ALT (U/L)
≤ 40	9	10	0.184
> 40	14	5
AST (U/L)
≤ 37	3	9	0.004
> 37	20	6
ALB (g/dL)
≤ 35	5	4	> 0.99
> 35	18	11
TBIL (μmol/L)
≤ 22	16	11	> 0.99
> 22	7	4
PT (sec)
≤ 14	19	21	0.665
> 14	4	2
AFP (ng/mL)
≤ 400	13	9	> 0.99
> 400	9	5
Child-pugh score
A	11	14	0.005
B	12	1
ECOG PS
0	8	12	0.009
1	15	3

HBV, hepatitis B virus; HCC, hepatocellular carcinomas; WBC, white blood cell; NEUT, neutrophil count; HB, hemoglobin; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; TBIL, total bilirubin; PT, prothrombin time; AFP, α-fetoprotein; ECOG, Eastern Cooperative Oncology Group; PS, performance status.

Table 5.

Predictive factors for TACE failure/refractoriness

Variable	Univariate analysis			Multivariate analysis
Variable	OR	95% CI	p-value	OR	95% CI	p-value
Age (> 50 yr vs. ≤ 50 yr)	0.563	0.151-2.096	0.391	-	-	-
AFP (> 400 μg/L vs. ≤ 400 μg/L)	1.246	0.312-4.977	0.755	-	-	-
Maximum tumor size (> 5 cm vs. ≤ 5 cm)	2.333	0.617-8.820	0.212	-	-	-
Tumor number (multiple vs. simple)	0.938	0.237-3.705	0.927	-	-	-
Vascular invasion (presence vs. absence)	19.000	3.604-100.154	0.001^**	18.204	1.392-238.090	0.027^*
Liver cirrhosis (presence vs. absence)	1.111	0.162-7.632	0.915	-	-	-
Ascites (presence vs. absence)	2.294	0.396-13.277	0.354	-	-	-
Child-Pugh classification (A vs. B)	15.273	1.714-136.126	0.015^*	23.352	0.767-710.623	0.071
ECOG PS (0 vs. 1)	0.145	0.031-0.677	0.014^*	0.192	0.008-4.742	0.192
TP53 mutation (presence vs. absence)	5.667	1.369-23.462	0.017^*	13.287	1.114-158.451	0.041^*

TACE, transcatheter arterial chemoembolization; OR, odds ratio; CI, confidence interval; AFP, α-fetoprotein; ECOG, Eastern Cooperative Oncology Group; PS, performance status; TP53, tumor protein p53.

^* p < 0.05,

^** p < 0.01.

Table 6.

Relationship between TP53mutation and TACE failure/refractoriness depending on presence or absence of vascular invasion

TP53 mutation	Without vascular invasion			With vascular invasion
TP53 mutation	Group A	Group B	p-value	Group A	Group B	p-value
Mutant type	7	1	0.041	10	4	0.386
Wild type	2	6		4	4

TP53, tumor protein p53; TACE, transcatheter arterial chemoembolization; group A, TACE failure/refractoriness group; group B, TACE effective group.

REFERENCES

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76. Article PubMed
2. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64:106–16. Article PubMed
3. Fan J, Zhou J, Wang JH, Qing SK, Zeng MS, Cong WM, et al. Guidance for diagnosis and treatment of primary liver cancer. Chin J Pract Surg. 2017;16:705–20.
4. Vesselle G, Quirier-Leleu C, Velasco S, Charier F, Silvain C, Boucebci S, et al. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol. 2016;26:1640–8. Article PubMed PDF
5. Jeong SO, Kim EB, Jeong SW, Jang JY, Lee SH, Kim SG, et al. Predictive factors for complete response and recurrence after transarterial chemoembolization in hepatocellular carcinoma. Gut Liver. 2017;11:409–16. Article PubMed PMC PDF
6. Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87 Suppl 1:22–31. Article PubMed
7. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149:1226–39. Article PubMed
8. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–62. Article PubMed
9. Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, et al. Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma. Hepatology. 2020;71:164–82. Article PubMed
10. Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, Tang ZY, et al. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology. 2011;140:1063–70. Article PubMed
11. Liu Q, Liu N, Shangguan Q, Zhang F, Chai W, Tong X, et al. LncRNA SAMD12-AS1 promotes cell proliferation and inhibits apoptosis by interacting with NPM1. Sci Rep. 2019;9:11593.Article PubMed PMC PDF
12. Kamat CD, Green DE, Warnke L, Thorpe JE, Ceriello A, Ihnat MA. Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett. 2007;249:209–19. Article PubMed
13. Mizuarai S, Yamanaka K, Kotani H. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res. 2006;66:6319–26. Article PubMed
14. Speidel D. The role of DNA damage responses in p53 biology. Arch Toxicol. 2015;89:501–17. Article PubMed PDF
15. Gouas DA, Villar S, Ortiz-Cuaran S, Legros P, Ferro G, Kirk GD, et al. TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis. 2012;33:1219–24. Article PubMed PMC PDF
16. Liao P, Zeng SX, Zhou X, Chen T, Zhou F, Cao B, et al. Mutant p53 gains its function via c-Myc activation upon CDK4 phosphorylation at serine 249 and consequent PIN1 binding. Mol Cell. 2017;68:1134–46. Article PubMed PMC
17. Chen ZX, Jian ZW, Wu XW, Wang JC, Peng JY, Lao XM. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. Cancer Med. 2019;8:5097–107. Article PubMed PMC
18. Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36. Article PubMed
19. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res. 1992;52:3674–8. PubMed
20. Dimri M, Humphries A, Laknaur A, Elattar S, Lee TJ, Sharma A, et al. NAD(P)H quinone dehydrogenase 1 ablation inhibits activation of the phosphoinositide 3-kinase/Akt serine/threonine kinase and mitogen-activated protein kinase/extracellular signal-regulated kinase pathways and blocks metabolic adaptation in hepatocellular carcinoma. Hepatology. 2020;71:549–68. Article PubMed
21. Chen L, Guo P, He Y, Chen Z, Chen L, Luo Y, et al. HCCderived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway. Cell Death Dis. 2018;9:513.Article PubMed PMC PDF
22. Xu G, Zhu L, Wang Y, Shi Y, Gong A, Wu C. Stattic enhances radiosensitivity and reduces radio-induced migration and invasion in HCC cell lines through an apoptosis pathway. Biomed Res Int. 2017;2017:1832494.Article PubMed PMC PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Concurrent Biopsy During Liver-Directed Therapy: Considerations, Techniques, and Expanding Role in Clinical Practice
Daniel M. DePietro, Ryan M. Kiefer, Kelley Weinfurtner, Matthew L. Hung
Digestive Disease Interventions.2026;[Epub] CrossRef
Advances in understanding the roles of TP53 mutations in pancreatic and hepatobiliary cancers
James A. McCubrey, Matilde Y. Follo, Stefano Ratti, Lucia Manzoli, Lucio Cocco, Melchiorre Cervello, Giuseppa Augello
Advances in Biological Regulation.2026; 101: 101169. CrossRef
Construction of ATOX1 targeted nano gel based on cuproptosis mechanism and its role in reversing TACE refractoriness of hepatocellular carcinoma
Chao Chen, Songlin Song, Wenlong Wu, Ningjun Yu, Chuansheng Zheng, Guofeng Zhou, Yanqiao Ren, Xiangjun Dong
Journal of Nanobiotechnology.2026;[Epub] CrossRef
Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study
Qi Fan, Pengcheng Wei, Delin Ma, Qian Cheng, Jie Gao, Jiye Zhu, Zhao Li
Surgery Open Science.2025; 23: 16. CrossRef
TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization
Ken Zhao, Anita Karimi, Luke Kelly, Elena Petre, Brett Marinelli, Erica S. Alexander, Vlasios S. Sotirchos, Joseph P. Erinjeri, Anne Covey, Constantinos T. Sofocleous, James J. Harding, William Jarnagin, Carlie Sigel, Efsevia Vakiani, Etay Ziv, Hooman Yar
Current Oncology.2025; 32(1): 51. CrossRef
Development and validation of nomogram including mutations in angiogenesis-related genes as risk factors for HCC patients treated with TACE
Wanqing Shen, Zhi Li, Jinyi Huang, Guixiong Zhang, Yiyang Tang, Wenzhe Fan, Jiaping Li
Translational Oncology.2025; 58: 102437. CrossRef
Hepatocellular Carcinoma Growth Kinetics and Outcomes After Transarterial Embolization: A Single-Center Analysis
Ken Zhao, Harrison Blume, Elena N. Petre, Dimitrios Xenos, Zuzanna Kobus, Erica S. Alexander, Vlasios S. Sotirchos, Ruben Geevarghese, Anne Covey, Joseph P. Erinjeri, Etay Ziv, Constantinos T. Sofocleous, James J. Harding, Kevin Soares, Carlie Sigel, Efse
Cancers.2025; 17(20): 3346. CrossRef
Efficacy and safety analysis of D-TACE combined with lenvatinib in the treatment of hepatocellular carcinoma refractory to C-TACE
Haohao Lu, Bin Liang, Chuansheng Zheng, Xiangwen Xia
BMC Gastroenterology.2025;[Epub] CrossRef
Clinical Therapy: HAIC Combined with Tyrosine Kinase Inhibitors and Programmed Cell Death Protein-1 Inhibitors versus HAIC Alone for Unresectable Hepatocellular Carcinoma
Baokun Liu, Lujun Shen, Wen Liu, Zhiyong Zhang, Jieqiong Lei, Zhengguo Li, Qinquan Tan, Hengfei Huang, Xingdong Wang, Weijun Fan
Journal of Hepatocellular Carcinoma.2024; Volume 11: 1557. CrossRef
Enhanced interactions within microenvironment accelerates dismal prognosis in HBV-related HCC after TACE
Libo Wang, Jiahui Cao, Zaoqu Liu, Shitao Wu, Yin Liu, Ruopeng Liang, Rongtao Zhu, Weijie Wang, Jian Li, Yuling Sun
Hepatology Communications.2024;[Epub] CrossRef
Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors
Kun Huang, Haikuan Liu, Yanqin Wu, Wenzhe Fan, Yue Zhao, Miao Xue, Yiyang Tang, Shi-Ting Feng, Jiaping Li
La radiologia medica.2024; 129(11): 1597. CrossRef
Identification of BRD7 by whole-exome sequencing as a predictor for intermediate-stage hepatocellular carcinoma in patients undergoing TACE
Kun Huang, Yanqin Wu, Wenzhe Fan, Yue Zhao, Miao Xue, Haikuan Liu, Yiyang Tang, Jiaping Li
Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11247. CrossRef
Prediction model of no-response before the first transarterial chemoembolization for hepatocellular carcinoma: TACF score
Jia-Wei Zhong, Dan-Dan Nie, Ji-Lan Huang, Rong-Guang Luo, Qing-He Cheng, Qiao-Ting Du, Gui-Hai Guo, Liang-Liang Bai, Xue-Yun Guo, Yan Chen, Si-Hai Chen
Discover Oncology.2023;[Epub] CrossRef
Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems
Jose J.G. Marin, Marta R. Romero, Elisa Herraez, Maitane Asensio, Sara Ortiz-Rivero, Anabel Sanchez-Martin, Luca Fabris, Oscar Briz
Seminars in Liver Disease.2022; 42(01): 087. CrossRef
Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma
Guixiong Zhang, Wenzhe Fan, Hongyu Wang, Jie Wen, Jizhou Tan, Miao Xue, Jiaping Li
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma
Wei-Li Xia, Shi-Jun Xu, Yuan Guo, Xiao-Hui Zhao, Hong-Tao Hu, Yan Zhao, Quan-Jun Yao, Lin Zheng, Dong-Yang Zhang, Chen-Yang Guo, Wei-Jun Fan, Hai-Liang Li
Frontiers in Oncology.2022;[Epub] CrossRef
Useful genes for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma
Yuan Guo, Hongtao Hu, Shijun Xu, Weili Xia, Hailiang Li
Journal of Cancer Research and Therapeutics.2022; 18(7): 1860. CrossRef
Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
Tian-Cheng Wang, Tian-Zhi An, Jun-Xiang Li, Zi-Shu Zhang, Yu-Dong Xiao
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Transcatheter arterial chemoembolization followed by surgical resection for hepatocellular carcinoma: a focus on its controversies and screening of patients most likely to benefit
Zhan-Qi Wei, Yue-Wei Zhang
Chinese Medical Journal.2021; 134(19): 2275. CrossRef
Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
Young Chang, Soung Won Jeong, Jae Young Jang, Yong Jae Kim
International Journal of Molecular Sciences.2020; 21(21): 8165. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma

Cancer Res Treat. 2020;52(3):925-937. Published online March 30, 2020

DOI: https://doi.org/10.4143/crt.2019.533

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
NOTES
REFERENCES

Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma

Fig. 1. Flow chart of enrolled patients. HCC, hepatocellular carcinoma; WES, whole-exome sequencing; TACE, transcatheter arterial chemoembolization; CT, computed tomography; MRI, magnetic resonance imaging.

Fig. 2. Heatmap of somatic genetic alterations in significant variation genes between groups A and B. Group A is defined as a group where transcatheter arterial chemoembolization (TACE) failure/refractoriness. And group B is defined as a group which can benefit from TACE therapy. Top and right panel shows the frequency of somatic mutation, middle panel shows patients ID, mutational spectra of single-nucleotide variants in different group, and types of mutation are indicated in the legend at the bottom (n=38). We found that the occurrence probability of TP53 and FLG mutations in the invalid group was significantly higher than that in group A. T>G mutation did not occur in group A during the transformation and alteration.

Fig. 3. Distribution of somatic mutations in the TP53 gene. The structural domains of TP53 mutations were different between the two groups, and the occurrence probability of TP53 R249S mutation in group A was higher than that in group B. Alteration frequency was represented as a percentage of significant variation genes in two groups: the left box represents group A and the right represents group B. Alteration types and frequencies were represented by different colors and color gradients, respectively.

Fig. 4. TP53 mutated and wild-type cases were compared before and after transcatheter arterial chemoembolization (TACE) by using computed tomography (CT) scan. For TP53 mutated case in A, plain sweep, augmentation, and portal phase were shown respectively in a, b, and c before TACE, while they were shown in d, e, and g after TACE. We found that TACE failure/refractoriness was assessed in the TP53 mutated case. Meanwhile, the TP53 wild-type case was shown in B and effective for TACE. The two cases were evaluated according to the criteria mentioned above.

Fig. 5. Frequently altered cancer pathways for TP53 using gene set enrichment analysis pathway enrichment in hepatocellular carcinoma. Core pathway analysis identified frequent genomic alterations in multiple cancer pathways including mitogen-activated protein kinase and apoptosis. MAPK, mitogen-activated protein kinase.

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma

Characteristic	No. (%) (n=38)
Age, mean±SD (yr)	50±11.5
Sex (male/female)	37/1
Cirrhosis (present/absent)	33/5
Ascites (present)	12 (31.6)
Maximum tumor size (> 5 cm)	21 (55.3)
Tumor number (multifocal)	29 (76.3)
Vascular invasion	22 (57.9)
ALB (g/L)	37.4±16.6
TBIL (μmol/L)	16.3±20.8
PT (sec)	12.4±0.9
AFP (> 400 ng/mL)	21 (55.3)
ECOG PS (0/1)	19/19
Child-Pugh (A/B)	31/7
BCLC stage (B/C)	16/22

Gene	Gene description	No. of patients	Sites
TP53	Tumor protein p53	22	21
MYC	Proto-oncogene, bHLH transcription factor	9	-
FGF	Fibroblast growth factor	9	-
BRCA	DNA repair associated	8	8
JAK1	Janus kinase 1	6	5
NOTCH	Neurogenic locus notch homolog	6	6
SOX2	SRY-box transcription factor 2	5	-
CTNNB1	Catenin beta 1	5	4
PTEN	Phosphatase and tensin homolog	4	3
RB1	RB transcriptional corepressor 1	4	4
TERT (exons)	Telomerase reverse transcriptase	3	3
RAS	Resistance to audiogenic seizures	3	-
ALK	Receptor tyrosine kinase	1	1

	Group A (n=23)	Group B (n=15)	p-value
TP53
No mutation	6	10
Mutation (+)	17	5	0.020
MYC
No mutation	16	13
Mutation (+)	7	2	0.273
FGF
No mutation	16	13
Mutation (+)	7	2	0.273
BRCA
No mutation	18	12
Mutation (+)	5	3	0.371
JAK1
No mutation	15	12
Mutation (+)	3	3	0.663
NOTCH
No mutation	19	13
Mutation (+)	4	2	1.000
SOX2
No mutation	20	13
Mutation (+)	3	2	1.000
CTNNB1
No mutation	21	12
Mutation (+)	2	3	0.365
PTEN
No mutation	20	14
Mutation (+)	3	1	1.000
RB1
No mutation	19	15
Mutation (+)	4	0	0.138
TERT (exons)
No mutation	21	14
Mutation (+)	2	1	1.000
RAS
No mutation	23	12
Mutation (+)	0	3	0.054
ALK
No mutation	23	14
Mutation (+)	0	1	0.395

Variable	Group A (n=23)	Group B (n=15)	p-value
Age (yr)
≤ 50	14	7	0.509
> 50	9	8
Cirrhosis
Absence	3	2	> 0.99
Presence	20	12
Ascites
Absence	17	13	0.440
Presence	6	2
Maximum tumor size (cm)
≤ 5	9	9	0.320
> 5	14	6
Tumor number
Simple	8	5	> 0.99
Multiple	15	10
Vascular invasion
Absence	4	12	< 0.001
Presence	19	3
WBC (×10⁹/L)
≤ 10	19	14	0.630
> 10	4	1
NEUT (×10⁹/L)
≤ 6.4	17	14	0.209
> 6.4	6	1
HB (g/L)
≤ 120	7	2	0.273
> 120	16	13
PLT (×10⁹)
≤ 100	4	2	> 0.99
> 100	19	13
ALT (U/L)
≤ 40	9	10	0.184
> 40	14	5
AST (U/L)
≤ 37	3	9	0.004
> 37	20	6
ALB (g/dL)
≤ 35	5	4	> 0.99
> 35	18	11
TBIL (μmol/L)
≤ 22	16	11	> 0.99
> 22	7	4
PT (sec)
≤ 14	19	21	0.665
> 14	4	2
AFP (ng/mL)
≤ 400	13	9	> 0.99
> 400	9	5
Child-pugh score
A	11	14	0.005
B	12	1
ECOG PS
0	8	12	0.009
1	15	3

Variable	Univariate analysis			Multivariate analysis
Variable	OR	95% CI	p-value	OR	95% CI	p-value
Age (> 50 yr vs. ≤ 50 yr)	0.563	0.151-2.096	0.391	-	-	-
AFP (> 400 μg/L vs. ≤ 400 μg/L)	1.246	0.312-4.977	0.755	-	-	-
Maximum tumor size (> 5 cm vs. ≤ 5 cm)	2.333	0.617-8.820	0.212	-	-	-
Tumor number (multiple vs. simple)	0.938	0.237-3.705	0.927	-	-	-
Vascular invasion (presence vs. absence)	19.000	3.604-100.154	0.001^**	18.204	1.392-238.090	0.027^*
Liver cirrhosis (presence vs. absence)	1.111	0.162-7.632	0.915	-	-	-
Ascites (presence vs. absence)	2.294	0.396-13.277	0.354	-	-	-
Child-Pugh classification (A vs. B)	15.273	1.714-136.126	0.015^*	23.352	0.767-710.623	0.071
ECOG PS (0 vs. 1)	0.145	0.031-0.677	0.014^*	0.192	0.008-4.742	0.192
TP53 mutation (presence vs. absence)	5.667	1.369-23.462	0.017^*	13.287	1.114-158.451	0.041^*

TP53 mutation	Without vascular invasion			With vascular invasion
TP53 mutation	Group A	Group B	p-value	Group A	Group B	p-value
Mutant type	7	1	0.041	10	4	0.386
Wild type	2	6		4	4

Table 1. Baseline characteristics of enrolled HCC patients

Table 2. Significantly mutated genes in 38 HBV-related advanced HCC patients

HBV, hepatitis B virus; HCC, hepatocellular carcinomas; -, none.

Table 3. The association of driver genes mutation and TACE failure/refractoriness

TACE, transcatheter arterial chemoembolization; TP53, tumor protein p53; MYC, proto-oncogene; FGF, fibroblast growth factor; JAK1, Janus kinase 1; NOTCH, neurogenic locus notch homolog; SOX2, SRY-box transcription factor 2; CTNNB1, catenin beta 1; PTEN, phosphatase and tensin homolog; RB1, RB transcriptional corepressor 1; TERT, telomerase reverse transcriptase; ALK, anaplastic lymphoma kinase; -, none.

Table 4. Clinical characteristic in 38 HBV-related advanced HCC patients

Table 5. Predictive factors for TACE failure/refractoriness

p < 0.05,

p < 0.01.

Table 6. Relationship between TP53mutation and TACE failure/refractoriness depending on presence or absence of vascular invasion

TP53, tumor protein p53; TACE, transcatheter arterial chemoembolization; group A, TACE failure/refractoriness group; group B, TACE effective group.